Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades

(2011) Avishay Elis et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia

(2011) Marit S. Nenseter et al.   ATHEROSCLEROSIS

ESC/EAS Guidelines for the management of dyslipidaemias

(2011) Alberico L. Catapano et al.   ATHEROSCLEROSIS

760 MIPOMERSEN AN APOB SYNTHESIS INHIBITOR EVALUATION OF POTENTIAL TO REDUCE NECESSITY FOR LIPID-APHERESIS IN PATIENTS WITH HETEROZYGOUS FH AND CAD

(2011) K.G. Parhofer et al.   ATHEROSCLEROSIS SUPPLEMENTS

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

(2011) Damon A Bell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice

(2011) Adam E. Mullick et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

(2011) Stefania Lamon-Fava et al.   JOURNAL OF LIPID RESEARCH

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

(2010) Fatima Akdim et al.   AMERICAN JOURNAL OF CARDIOLOGY

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

(2010) Terje R. Pedersen et al.   AMERICAN JOURNAL OF CARDIOLOGY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions

(2010) Mary McGowan   Journal of Clinical Lipidology

Novel therapies and new targets of treatment for familial hypercholesterolemia

(2010) Anne Carol Goldberg   Journal of Clinical Lipidology

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal

(2010) Roeland Huijgen et al.   PLoS One

The LDL Receptor

(2009) Joseph L. Goldstein et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Efficacy criteria and cholesterol targets for LDL apheresis

(2009) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)

(2009) U. Kassner et al.   ATHEROSCLEROSIS SUPPLEMENTS

A systematic review and meta-analysis on the therapeutic equivalence of statins

(2009) T.-C. Weng et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

(2009) Maartje E. Visser et al.   JOURNAL OF LIPID RESEARCH

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

(2008) Rosie Z. Yu et al.   BIOCHEMICAL PHARMACOLOGY

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

(2008) Rosie Z Yu et al.   CLINICAL PHARMACOKINETICS